Comparative Pharmacology
Head-to-head clinical analysis: ALDOCLOR 150 versus MICARDIS HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDOCLOR 150 versus MICARDIS HCT.
ALDOCLOR-150 vs MICARDIS HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 mL/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Telmisartan: terminal half-life ≈24 hours, allowing once-daily dosing. Hydrochlorothiazide: 6-15 hours (mean 10 hours).
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Primarily biliary excretion (≈60%) and renal excretion (≈40%) as unchanged drug. Telmisartan: renal <1%, fecal >97%. Hydrochlorothiazide: renal >95% unchanged.
Category C
Category C
Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic)
Antihypertensive Combination (ARB + Thiazide Diuretic)